Skin-electrode blood flow device for monitoring deep vein thrombosis during clot-dissolving treatment
Tests a skin-sensor device in people with deep vein thrombosis.
Key facts
- Who runs it
- Tampere University
- Where
- Finland2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Impedance Plethysmography Based Deep Vein Thrombosis Monitoring During Catheter-directed Thrombolysis
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 17 Jul 2025
- Expected to end
- Dec 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- Impedance plethysmography IPG
- Venous Occlusion Plethysmography VOP
- Breathing and leg movement exercise
- Record updated
- 29 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a blood clot in a deep leg vein (DVT) who are having catheter-directed thrombolysis (CDT), and for healthy volunteers. A skin-electrode device will measure blood flow in the legs.
- Age
- 18 years or older
- Sex
- All
- Disease stage
- Patient group: a DVT found in a lower limb, and able to have CDT treatment (clot-dissolving medicine given through a thin tube). Healthy group: no DVT.
Main reasons for not taking part
- Under 18 years of age
- Not able to give informed consent
- Skin in the measurement area too injured
- Healthy volunteers: a diagnosed DVT in the legs
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age: 18 or older
- DVT detected on other lower limb
- Suitable for CDT treatment
- Ability to give informed consent
- Volunteering for the study
- Age: 18 or older
- Ability to give informed consent
- Volunteering for the study
Who cannot take part
- Age under 18 years
- Age under 18 years
- Inability to give informed consent
- Denial
- Too injured skin in the measurement area
- Diagnosed DVT in lower limbs
- Inability to give informed consent
- Denial
- Too injured skin in the measurement area
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to collect data on blood circulation using a multi-frequency impedance plethysmography device developed in the ThrombUS+ project. Impedance plethysmography (IPG) is a non-invasive method that measures changes in blood volume using electrodes placed on the skin. The collected data will be used for device development, the improvement of diagnostic data analysis methods, and AI training.
Read full original descriptionShow less
A total of 40 participants will be recruited for this study, with 20 healthy volunteers in Tampere University and 20 patients undergoing thrombolytic therapy for DVT at Tampere University Hospital.
The 2 groups in the trial
- Patients
DVT detected on other lower limb, undergoing catheter-directed thrombolysis
Treatment: Impedance plethysmography IPG, Venous Occlusion Plethysmography VOP, and Breathing and leg movement exercise
- Healthy volunteers
Treatment: Impedance plethysmography IPG, Venous Occlusion Plethysmography VOP, and Breathing and leg movement exercise
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Impedance Plethysmography Based Deep Vein Thrombosis Monitoring During Catheter-directed Thrombolysis
- Plain-language title
- Skin-electrode blood flow device for monitoring deep vein thrombosis during clot-dissolving treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 29 June 2026